Conference Proceedings

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

Georgia J McCaughan, Steven Tran, Simon Durrant, Simon J Harrison, James Morton, Noemi Horvath, Andrew Spencer, Ian H Kerridge, Jeremy An Ke Er, Luani Barge, Adam Bryant, Robin J Filshie, Emily Choong, Hock Choong Lai, Campbell Tiley, Anthony K Mills, Andrew Butler, John Moore, Mark Hertzberg, Glen A Kennedy Show all

Blood | American Society of Hematology | Published : 2020


Background: Upfront autologous stem cell transplantation (ASCT) in multiple myeloma (MM) following induction therapy has been demonstrated to improve progression free survival (PFS) and overall survival (OS). Consideration of transplant eligibility involves assessment of age (typically <70 years), co-morbidities and frailty. In Australia and New Zealand, approximately 70% of all MM patients aged <70 years undergo upfront ASCT compared to approximately 6% aged 70-75 years (Bergin, MRDR Data). We aimed to review the patterns of transplantation in Australia and New Zealand in patients ≥70 years of age and examine survival outcomes and predictors of survival in this cohort. ..

View full abstract